<DOC>
	<DOCNO>NCT00253669</DOCNO>
	<brief_summary>RATIONALE : Patients gliomas may risk develop blood clot . Learning risk factor develop blood clot may help doctor plan good treatment glioma . PURPOSE : This clinical trial study risk factor develop blood clot patient undergo cancer treatment newly diagnose glioma .</brief_summary>
	<brief_title>Risk Factors Developing Blood Clot Patients Who Are Undergoing Cancer Treatment Newly Diagnosed Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall hazard rate first venous thromboembolism per person-year follow-up patient undergoing antineoplastic therapy newly diagnose high-grade glioma . - Correlate ABO blood type incidence venous thromboembolism patient . - Correlate factor VIII level incidence venous thromboembolism patient . Secondary - Determine overall individual incidence rate thromboembolism patient . - Correlate clinical variable , type antineoplastic treatment , Karnofsky performance status , type tumor , incidence venous thromboembolism patient . - Correlate demographic factor , age , incidence venous thromboembolism patient . OUTLINE : This pilot , multicenter study . Patients undergo blood collection blood typing ( already obtain ) factor VIII C-reactive protein level baseline . Patients follow obtain information Karnofsky performance status , treatment receive brain tumor , occurrence thrombotic event ( e.g. , pulmonary embolism deep-vein thrombosis ) . Patients follow every 28 day development thrombotic event , follow every 2 month survival . PROJECTED ACCRUAL : A total 107 patient accrue study .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose malignant brain tumor Supratentorial grade III IV astrocytoma 1 follow type : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme No prior thrombotic event PATIENT CHARACTERISTICS : Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy biologic agent , include immunotoxins , immunoconjugates , antisense therapy , peptidereceptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte , lymphocyteactivated killer cell , gene therapy , brain tumor Chemotherapy No prior chemotherapy brain tumor except polifeprosan 20 carmustine implant ( Gliadel wafer ) Endocrine therapy No prior hormonal therapy brain tumor except glucocorticoid Radiotherapy No prior radiotherapy brain tumor No prior cranial irradiation Other No concurrent chronic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>